Edgewise Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 26, 2026
| | | |
|---|---|---|
| | EDGEWISE THERAPEUTICS, INC. | |
| | | |
| | By: | /s/ Kevin Koch |
| | Name: | Kevin Koch |
| | Title: | President, Chief Executive Officer and Director |
| | | (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | | |
|---|---|---|---|---|
| Signature | | Title | | Date |
| | | | | |
| /s/ Kevin Koch | | President, Chief Executive Officer and Director | | February 26, 2026 |
| Kevin Koch, Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Michael Nofi | | Chief Financial Officer | | February 26, 2026 |
| Michael Nofi | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ Peter Thompson | | Co-Founder, Chairman and Director | | February 26, 2026 |
| Peter Thompson, M.D. | | | | |
| | | | | |
| /s/ Alan Russell | | Chief Scientific Officer and Director | | February 26, 2026 |
| Alan Russell, Ph.D. | | | | |
| | | | | |
| /s/ Laura A. Brege | | Director | | February 26, 2026 |
| Laura A. Brege | | | | |
| | | | | |
| /s/ Badreddin Edris | | Co-Founder and Director | | February 26, 2026 |
| Badreddin Edris, Ph.D. | | | | |
| | | | | |
| /s/ Jonathan Fox | | Director | | February 26, 2026 |
| Jonathan Fox, M.D., Ph.D., FACC | | | | |
| | | | | |
| /s/ Christopher Martin | | Director | | February 26, 2026 |
| Christopher Martin | | | | |
| | | | | |
| /s/ Arlene Morris | | Director | | February 26, 2026 |
| Arlene Morris | | | | |
| | | | | |
| /s/ Jonathan Root | | Director | | February 26, 2026 |
| Jonathan Root, M.D. | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.